Opportunity Information: Apply for RFA IP08 80303SUPP10
Apply for RFA IP08 80303SUPP10
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Immunization Grants and Vaccines for Children Program Supplemental for Pandemic Flu Aggregate Reporting of Pandemic Influenza Vaccine Utilization Monitoring" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.268 Immunization Cooperative Agreements.
- This funding opportunity was created on Aug 12, 2010 and posted on Aug 12, 2010.
- Applicants must submit their applications by Aug 30, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $754,006.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $150,000.00 in funding.
- The number of recipients for this funding is limited to 7 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- IV. ELIGIBILITY Limited Competition There are currently 62 project areas funded under FOA IP08 803 who have the necessary infrastructure in place to perform the activities required and have the experience needed to successfully complete the required functions and who have the primary responsibility for carrying out the public health assurance functions required to achieve the desired outcomes and performance goals established by CDC. Included among these grantees are the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Mariana Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau. This announcement is for Phase 1, Round 3 funding. Phase 1, Round 1and 2 funds were awarded through announcements FOA IP 08 803, and FOA IP08 803SUPP09 and RFA ATP08 802 to Project Areas for similar activities as those described in the Activities Section of this announcement. Project Areas who received Phase 1, Round 1 or 2 funding under the above mentioned announcements will not be considered for funding under Round 3. Funds for Round 1 were awarded to Project Areas Delaware, Florida, Idaho, Illinois, Iowa, Louisiana, Maine, Montana, New York City, Oregon and Washington Round 2 funds were awarded to Alaska, Arkansas, Mississippi, Federated States of Micronesia, Nevada, Philadelphia, and Wyoming and RFA TP08 802 funds were awarded to Colorado, Hawaii, Illinois, Michigan, Minnesota, New York City and North Dakota
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Immunization Grants and Vaccines for Children Program Supplemental for Pandemic Flu Aggregate Reporting of Pandemic Influenza Vaccine Utilization Monitoring" (Funding Opportunity Number RFA IP08 80303SUPP10) is a CDC discretionary grant designed to strengthen public health protection during an influenza pandemic by improving the tracking and reporting of pandemic influenza vaccine use. In practical terms, it supports public health agencies in monitoring how pandemic flu vaccine is being utilized so that vaccination efforts can be managed effectively, gaps can be identified quickly, and decision-makers can see reliable aggregate information about vaccine administration. The program aligns with the Healthy People 2010 focus area on Immunization and Infectious Diseases and is grounded in the reality that influenza pandemics can lead to significant illness and death along with major social and economic disruption across the United States.
This supplemental funding sits within CDCs broader pandemic influenza vaccine planning mission, which centers on minimizing the impact of a pandemic by enabling the manufacture, distribution, and administration of safe and effective pre-pandemic and pandemic influenza vaccines. While the language emphasizes vaccine planning in general, the specific focus of this award is on utilization monitoring and aggregate reporting, meaning the ability of awardees to collect, compile, and report vaccine use data in a way that supports situational awareness and accountability during a fast-moving public health emergency. The intent is to ensure that public health authorities have actionable visibility into vaccine uptake and administration patterns rather than relying on delayed or incomplete information.
The award mechanism is a grant under the health activity category, tied to CFDA number 93.268 (Immunization Cooperative Agreements). The CDC anticipated making 7 awards under this announcement, with an estimated total funding amount of $754,006. Individual awards were expected to fall between $50,000 (award floor) and $150,000 (award ceiling). There is no cost sharing or matching requirement, which means recipients would not be required to provide non-federal funds to receive or maintain the award.
Eligibility is limited and structured as a competitive supplement among a defined universe of existing immunization cooperative agreement project areas. Specifically, CDC limited competition to the project areas already funded under FOA IP08 803, because these jurisdictions already have the infrastructure and operational experience needed to carry out the required reporting and monitoring functions. This includes many U.S. states and certain local and territorial public health jurisdictions, as well as several U.S.-affiliated Pacific Island jurisdictions. The announcement explicitly notes that eligible grantees include the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Mariana Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau, among others funded under the underlying cooperative agreement.
This specific announcement is described as Phase 1, Round 3 funding. A key constraint is that project areas that already received Phase 1, Round 1 or Round 2 funding for similar activities were not eligible to be considered for Round 3. The notice lists which jurisdictions received earlier rounds: Round 1 awards went to Delaware, Florida, Idaho, Illinois, Iowa, Louisiana, Maine, Montana, New York City, Oregon, and Washington; Round 2 awards went to Alaska, Arkansas, Mississippi, the Federated States of Micronesia, Nevada, Philadelphia, and Wyoming. It also references related funding under RFA TP08 802, which supported Colorado, Hawaii, Illinois, Michigan, Minnesota, New York City, and North Dakota. The effect of these restrictions is that Round 3 was meant to extend similar pandemic influenza vaccine utilization monitoring capabilities to additional project areas that had not yet been supported through the earlier rounds.
The application timeline for this opportunity was short and specific to 2010. The opportunity was posted and created on August 12, 2010, with an original and current closing date of August 30, 2010, and an archive date of September 29, 2010. The sponsoring agency was the Centers for Disease Control and Prevention. For applicants or interested parties who had trouble accessing the full announcement, the provided point of contact was the CDC Procurement and Grants Technical Information Management Section, reachable by phone at 770-488-2700 or by email at PGOTIM@CDC.GOV.
Overall, this funding opportunity is best understood as targeted, time-sensitive supplemental support for existing public health immunization awardees to improve aggregate reporting on pandemic influenza vaccine utilization. The central public health value is stronger visibility into vaccine administration during a pandemic response, helping CDC and jurisdictions manage distribution, measure uptake, and respond to emerging needs with better data.
Frequently Asked Questions (FAQs)
What is the official title of this grant opportunity?
The opportunity is titled "Immunization Grants and Vaccines for Children Program Supplemental for Pandemic Flu Aggregate Reporting of Pandemic Influenza Vaccine Utilization Monitoring."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA IP08 80303SUPP10.
Which federal agency is sponsoring this funding opportunity?
The sponsoring agency is the Centers for Disease Control and Prevention (CDC).
What kind of funding mechanism is this?
This is a CDC discretionary grant under the health activity category, tied to CFDA 93.268 (Immunization Cooperative Agreements).
What is the main purpose of this supplemental grant?
The purpose is to strengthen public health protection during an influenza pandemic by improving tracking and aggregate reporting of pandemic influenza vaccine use. In practical terms, it supports monitoring how pandemic flu vaccine is being utilized so officials can manage vaccination efforts, spot gaps quickly, and rely on more timely, reliable aggregate information about vaccine administration.
What does "utilization monitoring and aggregate reporting" mean in this context?
It refers to the ability to collect, compile, and report data on pandemic influenza vaccine use at an aggregate level so that public health authorities have situational awareness and accountability during a fast-moving emergency, rather than depending on delayed or incomplete information.
How does this opportunity fit into CDC's broader pandemic influenza efforts?
This supplemental funding sits within CDC's broader pandemic influenza vaccine planning mission, which aims to minimize the impact of a pandemic by enabling the manufacture, distribution, and administration of safe and effective pre-pandemic and pandemic influenza vaccines. This specific award focuses on monitoring vaccine use and reporting utilization data.
What public health goals or frameworks does this program align with?
The program aligns with the Healthy People 2010 focus area on Immunization and Infectious Diseases and reflects the concern that influenza pandemics can cause significant illness and death as well as major social and economic disruption across the United States.
How many awards did CDC anticipate making under this announcement?
CDC anticipated making 7 awards under this announcement.
What was the estimated total funding amount for this round?
The estimated total funding amount was $754,006.
What were the expected minimum and maximum award amounts?
Individual awards were expected to range from $50,000 (award floor) to $150,000 (award ceiling).
Is there a cost sharing or matching requirement?
No. There is no cost sharing or matching requirement, meaning recipients are not required to provide non-federal funds to receive or maintain the award.
Who is eligible to apply?
Eligibility is limited to a competitive supplement among a defined universe of existing immunization cooperative agreement project areas. CDC limited competition to project areas already funded under FOA IP08 803 because those jurisdictions already have the infrastructure and operational experience needed for the required reporting and monitoring functions.
Does the announcement list examples of eligible jurisdictions?
Yes. The announcement explicitly notes eligible grantees include the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Mariana Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau, among others funded under the underlying cooperative agreement.
What does "Phase 1, Round 3" mean for this funding?
This announcement is described as Phase 1, Round 3 funding. It is a targeted round intended to extend pandemic influenza vaccine utilization monitoring capabilities to additional project areas that had not yet been supported through earlier rounds.
Were any jurisdictions not eligible because they already received earlier rounds of funding?
Yes. Project areas that already received Phase 1, Round 1 or Round 2 funding for similar activities were not eligible to be considered for Round 3.
Which jurisdictions received Phase 1, Round 1 awards?
Round 1 awards went to Delaware, Florida, Idaho, Illinois, Iowa, Louisiana, Maine, Montana, New York City, Oregon, and Washington.
Which jurisdictions received Phase 1, Round 2 awards?
Round 2 awards went to Alaska, Arkansas, Mississippi, the Federated States of Micronesia, Nevada, Philadelphia, and Wyoming.
Does the notice reference any related funding opportunities?
Yes. It references related funding under RFA TP08 802, which supported Colorado, Hawaii, Illinois, Michigan, Minnesota, New York City, and North Dakota.
Why was competition limited to existing FOA IP08 803 project areas?
CDC limited competition to these jurisdictions because they already have the infrastructure and operational experience needed to carry out the required utilization monitoring and aggregate reporting functions during a pandemic response.
What were the key dates for this opportunity?
The opportunity was posted and created on August 12, 2010. The original and current closing date was August 30, 2010. The archive date was September 29, 2010.
Is this opportunity still open?
No. Based on the listed closing date (August 30, 2010) and archive date (September 29, 2010), this opportunity is archived and was time-limited to 2010.
What should someone do if they had trouble accessing the full announcement at the time?
The notice provided a point of contact: the CDC Procurement and Grants Technical Information Management Section, reachable by phone at 770-488-2700 or by email at PGOTIM@CDC.GOV.
What is the central value of this funding during a pandemic?
The central value is stronger visibility into vaccine administration during a pandemic response, helping CDC and jurisdictions manage distribution, measure uptake, identify gaps, and respond to emerging needs using better aggregate data.
Browse more opportunities from the same agency: Centers for Disease Control and Prevention
Browse more opportunities from the same category: Health
Next opportunity: BLM OR/WA Finding Fremont Travelling Exhibit, Lakeview District, Oregon
Previous opportunity: BLM OR/WA National Landscape Conservation System/Yaquina Head Outstanding Natural Area Seabird Study
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA IP08 80303SUPP10
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA IP08 80303SUPP10) also looked into and applied for these:
| Funding Opportunity |
|---|
| Neurobiology of Migraine (R01) Apply for PA 10 258 Funding Number: PA 10 258 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| PS10 1001 HIV Prevention Projects Supplemental Resources to Enhance HIV Prevention Strategies Apply for CDC RFA PS10 10010601SUPP10 Funding Number: CDC RFA PS10 10010601SUPP10 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Science of Structure, Organization and Practice Design in the Efficient Delivery of Effective Healthcare (R21) Apply for RFA RM 10 016 Funding Number: RFA RM 10 016 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Global Infectious Disease Research Training Program (D43) Apply for PAR 10 260 Funding Number: PAR 10 260 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Economics of Prevention (R21) Apply for RFA RM 10 015 Funding Number: RFA RM 10 015 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Enhanced Comprehensive HIV Prevention Planning and Implementation for Metropolitan Statistical Areas Most Affected by HIV/AIDS Apply for CDC RFA PS10 10181 Funding Number: CDC RFA PS10 10181 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,750,000 |
| State Competitive Supplemental Funding for Behavioral Risk Factor Surveillance System Apply for CDC RFA DP09 90103 SUPP10 Funding Number: CDC RFA DP09 90103 SUPP10 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Limited Pilot for NIGMS Legacy Community Wide Scientific Resources (R24) Apply for PAR 10 261 Funding Number: PAR 10 261 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Scalable Assays for Unbiased Analysis of Neurobiological Function (R01) Apply for RFA MH 11 040 Funding Number: RFA MH 11 040 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Ryan White Part A HIV Emergency Relief Grant Program Apply for HRSA 11 062 Funding Number: HRSA 11 062 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Planning Grant for Global Infectious Disease Research Training Program (D71) Apply for PAR 10 262 Funding Number: PAR 10 262 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Behavioral Mechanisms in Biomedical Strategies to Prevent HIV Infections (R34) Apply for RFA MH 11 092 Funding Number: RFA MH 11 092 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Behavioral Mechanisms in Biomedical Strategies to Prevent HIV Infections (R01) Apply for RFA MH 11 090 Funding Number: RFA MH 11 090 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Behavioral Mechanisms in Biomedical Strategies to Prevent HIV Infections (R21) Apply for RFA MH 11 091 Funding Number: RFA MH 11 091 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Reinvigorating HIV Prevention for Men who have Sex with Men (R01) Apply for RFA MH 11 080 Funding Number: RFA MH 11 080 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Reinvigorating HIV Prevention for Men who have Sex with Men (R21) Apply for RFA MH 11 081 Funding Number: RFA MH 11 081 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Reinvigorating HIV Prevention for Men who have Sex with Men (R34) Apply for RFA MH 11 082 Funding Number: RFA MH 11 082 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Program to Expand and Assess the Health Effects Associated with Exposures to Volcanic Emission and Air Pollutants Apply for RFA EH08 0010301SUPP10 Funding Number: RFA EH08 0010301SUPP10 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $80,000 |
| Diagnosis and Management of Severe Febrile Illness Apply for USAID TANZANIA 10 010 RFA Funding Number: USAID TANZANIA 10 010 RFA Agency: Tanzania USAID Dar es Salaam Category: Health Funding Amount: $24,000,000 |
| Identification of Immune Mediated Causes of Sensorineural Hearing Loss (R21/R33) Apply for RFA DC 11 002 Funding Number: RFA DC 11 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA IP08 80303SUPP10", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.